Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 in Advanced Solid Tumors
NCT06057922Phase 2Active, not recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Sep 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of YL201 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by MediLink Therapeutics. Started Sep 2023; status: active, not recruiting.
02
Drugs
YL201
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)nasopharyngeal carcinoma (NPC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06057922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057922.